CN Patent

CN114761012B — 组合疗法

Assigned to Mirati Therapeutics Inc · Expires 2025-03-21 · 1y expired

What this patent protects

本发明涉及用于治疗KRas G12C癌症的组合疗法。具体地，本发明涉及治疗有需要的受试者的癌症的方法，其包括向所述受试者施用治疗有效量的阻断程序性死亡‑1受体(PD‑1)和程序性死亡配体‑1(PD‑L1)信号传导的药剂与式(I)、式I‑A或式I‑B的KRAS G12C抑制剂的组合；包含所述组合物的试剂盒和其使用方法。

USPTO Abstract

本发明涉及用于治疗KRas G12C癌症的组合疗法。具体地，本发明涉及治疗有需要的受试者的癌症的方法，其包括向所述受试者施用治疗有效量的阻断程序性死亡‑1受体(PD‑1)和程序性死亡配体‑1(PD‑L1)信号传导的药剂与式(I)、式I‑A或式I‑B的KRAS G12C抑制剂的组合；包含所述组合物的试剂盒和其使用方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN114761012B
Jurisdiction
CN
Classification
—
Expires
2025-03-21
Drug substance claim
No
Drug product claim
No
Assignee
Mirati Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.